drugset / Trial / NCT06457997
A Study of PHN-010 in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Timeline
- Start
- 2024-07-01
- Primary completion
- 2025-09-11
- Completion
- 2025-09-11
Outcome
Outcome not reported
Stopped (Business): “The study was terminated by Sponsor for strategic reasons.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PHN-010 | Other / unclassified | — | Intravenous |